St Louis, MO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The Food and Drug Administration has granted approval for Zepbound™, an innovative weight loss medication developed by Eli Lilly. In clinical trials, this groundbreaking drug demonstrated the potential to help individuals shed up to 52 pounds within a 16-month timeframe.

密苏里州圣路易斯，2023年11月10日（GLOBE NEWSWIRE）-食品和药物管理局已批准Zepbound™, 礼来公司开发的一种创新减肥药。在临床试验中，这种开创性的药物显示出有可能帮助个人在16个月的时间内减轻高达52磅的体重。

The active ingredient in Zepbound is tirzepatide, which is the same active ingredient in Mounjaro™, a drug made by the same pharmaceutical company. While Mounjaro is approved to treat Type 2 diabetes, Zepbound is the first tirzepatide medication approved specifically for weight loss.  Dr. Jay Michael Snow, board-certified bariatric surgeon and founder of St.

Zepbound的活性成分是tirzepatide，它与Mounjaro的活性成分相同™, 由同一制药公司制造的药物。虽然Mounjaro被批准用于治疗2型糖尿病，但Zepbound是第一个专门用于减肥的tirzepatide药物。Jay Michael Snow博士，董事会认证的减肥外科医生和St.的创始人。

Louis Bariatrics, welcomes the news of the FDA approval. He says, “the new class of injectable weight loss and diabetes medications, such as Ozempic, Wegovy, and Mounjaro, have revolutionized health and weight loss for patients in St. Louis. We look forward to expanding our medical weight loss options.”  Highlights of Zepbound: Approved for adults with obesity, as well as those who are overweight with at least one weight-related condition.

Louis Bariatrics，欢迎FDA批准的消息。他说，“新型注射减肥药和糖尿病药物，如Ozempic，Wegovy和Mounjaro，已经彻底改变了圣路易斯患者的健康和体重减轻，我们期待扩大我们的医疗减肥选择。”Zepbound的亮点：批准用于肥胖成人，以及超重至少有一种体重相关疾病的人。

It is estimated that Zepbound will be available to patients in St. Louis by the end of 2023 Expected pricing for Zepbound will be approximately 20% lower than that of Ozempic and Eli Lilly plans to introduce savings programs In clinical trials, patients lost an average of 22.5% of their body weight Zepbound falls into a category of medications called GLP-1 agonists, which simulate a hormone that aids in curbing food intake and appetite.

据估计，到2023年底，圣路易斯的患者可以使用Zepbound。预计Zepbound的价格将比Ozempic低约20%，礼来计划在临床试验中引入储蓄计划，患者平均损失22.5%的体重Zepbound属于一类称为GLP-1激动剂的药物，模拟有助于抑制食物摄入和食欲的激素。

What sets Zepbound apart is its ability to mimic a second hormone called GIP, which not only reduces appetite but also has the potential to enhance the body's metabolism of sugar and fat.  Similar to other GLP-1 medications, th.

使Zepbound与众不同的是它能够模仿称为GIP的第二种激素，这种激素不仅可以降低食欲，还具有增强身体糖和脂肪代谢的潜力。与其他GLP-1药物类似，th。